Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

NEW YORK and CLEVELAND, Jan. 19, 2017 (GLOBE NEWSWIRE) --ABO-101, Abeona's third AAV gene therapy program to receive EMA Orphan DesignationClinical trials anticipated to begin enrolling in second quarter 2017Natural History Study in 25 patients has established efficacy outcome measures...

London, 19/01/2017 (informazione.it - comunicati stampa - salute e benessere)